Source:http://linkedlifedata.com/resource/pubmed/id/12097278
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
2002-7-4
|
pubmed:abstractText |
A proportion of gastrointestinal neuroendocrine tumors are aggressive; however, little is known of molecular determinants of their growth, and molecular studies have identified no useful prognostic factors. Overexpression of HER-2/neu is common in some nonendocrine tumors, frequently correlates with increased tumor aggressiveness, and can be used as a basis of treatment with trastuzumab. Little is known of its expression in malignant pancreatic endocrine tumors. In the present study HER-2/neu gene amplification and expression was determined in 43 gastrinomas from different patients. Results were correlated with clinical, laboratory, and tumor characteristics including tumor growth. HER-2/neu gene amplification was assessed by differential PCR, mRNA levels assessed by quantitative PCR, and protein by immunohistochemistry. Fourteen percent of patients had HER-2/neu gene amplification in tumors compared with levels in their WBCs. HER-2/neu mRNA varied over a 700-fold range. However, only 3% exceeded levels seen in normal pancreas, and immunohistochemistry did not show protein overexpression in any tumor (n = 10). HER-2/neu mRNA levels were significantly higher (P = 0.032) in tumors associated with liver metastases but not with tumor location or size. These results show that HER-2/neu amplification/overexpression does not seem to play a role in the molecular pathogenesis of most gastrinomas, as suggested in a previous study involving small numbers of cases. However, mild gene amplification occurs in a subset, and overexpression is associated with aggressiveness. Therefore, HER-2/neu levels could have prognostic significance as well as identify a patient subset with gastrinomas who might benefit from trastuzumab treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3702-10
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:12097278-Adolescent,
pubmed-meshheading:12097278-Adult,
pubmed-meshheading:12097278-Cell Division,
pubmed-meshheading:12097278-Female,
pubmed-meshheading:12097278-Gastrinoma,
pubmed-meshheading:12097278-Gene Amplification,
pubmed-meshheading:12097278-Gene Expression,
pubmed-meshheading:12097278-Genes, erbB-2,
pubmed-meshheading:12097278-Humans,
pubmed-meshheading:12097278-Male,
pubmed-meshheading:12097278-Middle Aged,
pubmed-meshheading:12097278-Neoplasm Invasiveness,
pubmed-meshheading:12097278-Pancreatic Neoplasms,
pubmed-meshheading:12097278-Receptor, erbB-2,
pubmed-meshheading:12097278-Tumor Cells, Cultured
|
pubmed:year |
2002
|
pubmed:articleTitle |
Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
|
pubmed:affiliation |
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-1804, USA.
|
pubmed:publicationType |
Journal Article
|